AllaQuix™ is a professional-grade hemostat. AllaQuix™ is a sterile, topical, active hemostatic, wound dressing.
AllaQuix™ has been cleared by FDA for over the counter (OTC) use for management of minor topical bleeding wounds such as minor abrasions and minor skin lacerations
AllaQuix™ is made from medical-grade chitosan. Chitosan is a naturally occurring, biocompatible polysaccharide.
Chitosan has a long history as a hemostat. Early work on using chitosan in medical applications, specifically for hemostasis started with Malette and Quigley in the 1980s. In the three decades since, there have been numerous published studies on the safety and efficacy of chitosan as a hemostat. This research and the positive findings have led to the introduction of several chitosan-based hemostats in use by medical professionals. Chitosan-based hemostats have been prevalent in surgical and trauma settings, where severe bleeding needs to be controlled quickly. In addition, the US military has used chitosan-based hemostats, with one branch of the military including a chitosan-based hemostat in their improved first aid kits.
Chitosan is a widely used hemostat because it exhibits many beneficial properties in medicine including:
- The rapid control of bleeding or hemostasis
- Antimicrobial activity and the
- Stimulation of wound healing
A key advantage of chitosan as a hemostat is that it acts independent of the clotting cascade. It is this property of chitosan that allows it work even in people that have genetic conditions that cause bleeding or clotting disorders and those people on medications that interfere with the clotting mechanism, such as anticoagulants.
The hemostasis caused by chitosan is initiated independent of platelets or coagulation factors. Chitosan can form a stable coagulum with blood in the absence of fibrin. In this micrograph, the heparinized blood has formed a bond with the fibers of the chitosan to form a stable coagulum. These results have been duplicated in several studies. It has been shown that chitosan can induce hemostasis with washed red blood cells alone.
Hemostasis induced by chitosan is attributed to the physical interaction between chitosan and the cell membranes of red blood cells. There is an interaction between the positively charged chitosan polymer and the negatively charged cell membrane of the red blood cell. This ionic interaction is responsible for coagulum formed by chitosan.
AllaQuix™ is designed to work in everyone. The chitosan fibers in AllaQuix™ are processed with a patent-pending, proprietary technology. The advanced surface-treated fiber is designed to aggregate platelets along the fiber to accelerate clot formation even when anticoagulation therapies are used. Once the AllaQuix™ hemostatic pad is on the wound, the chitosan fibers in AllaQuix™ attract the red blood cells. When the red blood cells bind to the AllaQuix™ hemostatic pad, a seal over the wound and a tight, stable clot at the site of the wound are created. This tight, stable clot seals the wound and controls the bleeding
AllaQuix™ is what patients are looking for in a product to control bleeding:
- AllaQuix™ effectively controls bleeding, even if the body may have trouble controlling bleeding itself
- AllaQuix™ is easy-on/easy-off and can be used with or without adhesive
- AllaQuix™ causes no irritation, burning, or stinging at the site of the wound
- AllaQuix™ requires no preparation or mixing and no special storage conditions
- AllaQuix™ is a direct- from-the-shelf, rapid-deployment hemostasis pad
AllaQuix™ is for management of minor topical bleeding wounds such as minor abrasions and minor skin lacerations.
For medical emergencies, serious wounds, or if bleeding persists, seek immediate professional medical help. Does not replace stitches – seek medical attention if stitches needed. Do not use on visibly infected wounds – seek medical attention.
Longer compression time may be necessary for patients who have high blood pressure or are overweight.
AllaQuix™ is made from chitosan, which is derived from shellfish. Individuals with known shellfish allergies should exercise caution in the use of any product containing chitosan.
There have been no known allergic reactions or adverse events reported as a result of using Inspiration Medical Technology, Inc. chitosan products since distribution began.
Read full Instructions for Use before using AllaQuix™.
Acheson EM, Kheirabadi BS, Deguzman R, Dick EJ Jr, Holcomb JB. Comparison of hemorrhagic control agents applied to lethal extremity arterial hemorrhage in swine. J Trauma. 2005; 59:865-75.
Alam HB, Uy GB, Miller D, et al. Comparative analysis of hemostatic agents in a swine model of lethal groin injury. J Trauma. 2003; 54:1077–82.
Alam HB, Burris D, DaCorta JA, Rhee P. Hemorrhage control in the battlefield: role of new hemostatic agents. Mil Med. 2005; 170(1):63–9.
Balassa LL, Prudden JF. Applications of chitin and chitosan in wound-healing acceleration. In: Murrarelli RAA, Pariser ER (eds) Proceedings of the First International Conference on Chitin/Chitosan. Boston. 1978. 296–305 .
Brandenberg G, Leibrock LG, Shuman R, Malette WG, Quigley H. Chitosan: a new topical hemostatic agent for diffuse capillary bleeding in brain tissue. Neurosurgery. 1984;15:9–13.
Chan MW, Schwaitzberg SD, Demcheva M, Vournakis J, Finkielsztein S, Connolly RJ. Comparison of poly-N-acetyl glucosamine (P-GlcNAc) with absorbable collagen (Actifoam), and fibrin sealant (Bolheal) for achieving hemostasis in a swine model of splenic hemorrhage. J Trauma. 2000;48:454–458.
Chou, Tz-Chong, Earl Fu, Chang-Jer Wu, Jeng-Hsien Yeh. Chitosan enhances platelet adhesion and aggregation. Biochemical and Biophysical Research Communications. 2003; 302(3): 480–83.
Cole DJ, Connolly RJ, Chan MW, et al. A pilot study evaluating the efficacy of a fully acetylated poly-N-acetyl glucosamine membrane formulation as a topical hemostatic agent. J Surg. 1999;126:510–517.
Evans EE, Kent SP. The use of basic polysaccharides in histochemistry and cytochemistry: IV—precipitation and agglutination of biological materials by aspergillus polysaccharide and deacetylated chitin. J Histochem Cytochem. 1962; 10:24–28.
Fradet G, Brister S, Mulder DS, Lough J, Averbach BL. Evaluation of chitosan as a new hemostatic agent: In vitro and in vivo expression. In: Muzzarelli R, Gooday GW (eds) Chitin in nature and technology. Plenum, New York. 1986; 443–451.
Fukasawa M, Abe H, Masaoka T, et al. The hemostatic effect of deacylated chitin membrane on peritoneal injury in a rabbit model. Surg Today. 1992;22:333–338.
Janvikul, W, Uppanan, P, Thavornyutikarn, B, Krewraing, J. and Prateepasen, R. In vitrocomparative hemostatic studies of chitin, chitosan, and their derivatives. J. Appl. Polym. Sci., 1986; 102: 445–451.
Jewelewicz DD, Cohn SM, Crookes BA, Proctor KG. Modiﬁed rapid deployment hemostat bandage reduces blood loss and mortality in coagulopathic pigs with severe liver injury. J Trauma. 2003; 55:275–81.
Kind GM, Bines SD, Staren ED, Templeton AJ, Economou SG. Chitosan: evaluation of a new hemostatic agent. Curr Surg. 1990; 47:37–39.
Klollevold PR, Lew DS, Ellis DG, Bertolami CN. Effect of chitosan on lingual hemostasis in rabbits. J Oral Maxillofac Surg. 1991; 49:858–863.
Klokkevold PR, Subar P, Fukayama H, Bertolami CN. Effect of chitosan on lingual hemostasis in rabbits with platelet dysfunction induced by epoprostenol. J Oral Maxillofac Surg. 1992;50:41–45.
Klokkevold PR, Fukayama H, Sung EC, Bertolami CN. The effect of chitosan (poly-N-acetyl glucosamine) on lingual hemostasis in heparinized rabbits. J Oral Maxillofac Surg. 1999;57:49–52.
Komlos L, Ben-Efraim S, Lewis NJ, Hart J, Halbrecht I. Synergistic effect of N-acetyl-D-glucosamine (NAG) on mitogenic, antigenic and allogenic stimulation of normal lymphocytes. Int J Immunopharmacol. 1984;6:593–599.
Lord, MS, Cheng, B, McCarthy, SJ, Jung, MS, Whitelock, JM. The modulation of platelet adhesion and activation by chitosan through plasma and extracellular matrix proteins, Biomaterials. 2001: 32(28): 6655-62.
Lord, MS, Yu, W, Cheng, B, Simmons, A, Poole-warren, L, Whitelock, JM. The modulation of platelet and endothelial cell adhesion to vascular graft materials by perlecan. Biomaterials. 2009; 30(28): 4898–4906.
Malette WG, Quigley HJ, Gaines RD, Johnson ND, Rainer WG. Chitosan: A new hemostatic. Ann Thorac Surg. 1983; 36:55–58.
Malette WG, Quigley HJ Jr, Adickes ED. Chitosan effect in vascular surgery, tissue culture and tissue regeneration. In: Muzzarelli R, Gooday GW (eds) Chitin in nature and technology. Plenum, New York,. 1986; 435–442.
Minami S, Suzuki H, Okamato Y, Fujinaga T, Shigemasa Y. Chitin and chitosan activate complement via alternative pathway. Carbohydr Polym. 1998;36:151–155.
Mori T, Okumura M, Matsura M, et al. Effects of chitin and its derivatives on the proliferation and cytokine production of fibroblasts in vitro. Biomaterials. 1997;18:947–51.
Muzzarelli RA, Mattioli-Belmonte M, Pugnaloni A, Biagini G. Biochemistry, histology and clinical uses of chitins and chitosans in wound healing. In: Jolles P, Muzzarelli RA, eds. Chitin and Chitinases. Basel, Switzerland: Birkhauser Verlag; 1999:251–264.
Nishimura K, Nishimura S, Nishi N, Tokura S, Azuma I. Immunological activity of chitin derivatives. In: Muzzarelli R, Gooday GW (eds) Chitin in nature and technology. Plenum, New York. 1986; 477–83.
Okamoto, Y, Yano, R, Miyatake, K, Tomohiro, I, Shigemasa, Y. Minami, S. Effects of chitin and chitosan on blood coagulation. Carbohydrate Polymers. 2003; 53(3): 337-42
Peh KK, Khan TA, Ch’ng HS. Mechanical, bioadhesive strength and biological evaluation of chitosan films for wound dressing. J Pharm Pharm Sci. 2000;3:303–311.
Pruden JF, Migel P, Hanson P, Friedrich L, Balassa L. The discovery of a potent pure chemical wound-healing accelerator. Am J Surg. 1970;119:560–64.
Pusateri AE, Holcomb JB, Kheirabadi BS, Alam H, Wade CE, Ryan KL. Making sense of the preclinical literature on advanced hemostatic dressings. J Trauma. 2006; 60(3):674–82.
Pusateri AE, McCarthy SJ, Gregory KW, et al. Effect of a chitosan-based hemostatic dressing on blood loss and survival in a model of severe venous hemorrhage and hepatic injury in swine. J Trauma. 2003a; 54:177–82.
Rao, S. B. and Sharma, C. P. Use of chitosan as a biomaterial: Studies on its safety and hemostatic potential. J. Biomed. Mater. Res. 1997; 34: 21–28.
Schmidt RJ, Chung LY, Andrews AM, Spyratou O, Turner TD. Biocompatibility of wound management products: a study of the effects of various polysaccharides on murine L929 fibroblast proliferation and macrophage respiratory burst. J Pharm Pharmacol.1993;45:508–513.
Sugamori, T., Iwase, H., Maeda, M., Inoue, Y. and Kurosawa, H. Local hemostatic effects of microcrystalline partially deacetylated chitin hydrochloride. J. Biomed. Mater. Res. 2000; 49: 225–232.
Suzuki K, Tokoro A, Okawa Y, Suzuki S, Suzuki M. Effect of Nacetylchito-oligiosaccharides on activation of phagocytes. Microbiol Immunol. 1986;30:777–787.
Tanigawa T, Yoshinori T, Tomita K, et al. Effect of chitin on the production of interleukin-1b in human blood monocytes. Yonago Acta Med. 1992;35:147–150.
Tokura S, Tamura H, Azuma I. Immunological aspects of chitin and chitin derivatives administered to animals. In: Jolles P, Muzzarelli RA, eds. Chitin and Chitinases. Basel, Switzerland: Birkhauser Verlag; 1999:279–292.
Wedmore I, McManus JG, Pusateri AE, Holcomb JB. The chitosan-based hemostatic dressing: Experience in current combat operations. J Trauma. 2006; 60(3):655–8.
Yang, J., Tian, F., Wang, Z., Wang, Q., Zeng, Y.-J. and Chen, S.-Q. (2008), Effect of chitosan molecular weight and deacetylation degree on hemostasis. J. Biomed. Mater. Res., 84B: 131–137.